Valopicitabine (NM-283) is an antiviral drug which was developed as a treatment for hepatitis C, though only progressed as far as Phase III clinical trials. It acts as an RNA-dependent RNA polymerase inhibitor. It is a prodrug which is converted inside the body to the active form, 2'-C-methylcytidine triphosphate.[1][2][3][4][5]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H24N4O6 |
Molar mass | 356.379 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G (2005). "Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine". Nucleosides, Nucleotides & Nucleic Acids. 24 (5–7): 767–70. doi:10.1081/ncn-200060112. PMID 16248033. S2CID 23883085.
- ^ Toniutto P, Fabris C, Bitetto D, Fornasiere E, Rapetti R, Pirisi M (February 2007). "Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus". Current Opinion in Investigational Drugs. 8 (2): 150–8. PMID 17328231.
- ^ Liu-Young G, Kozal MJ (June 2008). "Hepatitis C protease and polymerase inhibitors in development". AIDS Patient Care and STDs. 22 (6): 449–57. doi:10.1089/apc.2007.0199. PMC 2928549. PMID 18479202.
- ^ Carroll SS, Koeplinger K, Vavrek M, Zhang NR, Handt L, MacCoss M, et al. (August 2011). "Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees". Antimicrobial Agents and Chemotherapy. 55 (8): 3854–60. doi:10.1128/AAC.01152-10. PMC 3147631. PMID 21628542.
- ^ Krecmerova M (2017). "Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals". Mini Reviews in Medicinal Chemistry. 17 (10): 818–833. doi:10.2174/1389557517666170216151601. PMID 28215138.